| Authors: |
Goldberg FW; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Ting AKT; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Beattie D; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Lamont GM; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Fallan C; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Finlay MRV; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Williamson B; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Schimpl M; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Harmer AR; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Adeyemi OB; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Nordell P; Biopharmaceuticals R&D, AstraZeneca, 431 50 Gothenburg, Sweden., Cronin AS; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Vazquez-Chantada M; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Barratt D; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Ramos-Montoya A; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Cadogan EB; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Davies BR; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K. |